Supernus Pharmaceuticals, Inc. (SUPN) earnings
SUPN earnings moved a median of +1.07% by the close. Quarterly and annual SUPN reports and results, each read against the price at its own news timestamp. Back to the SUPN overview →
30 measured SUPN earnings events.
Where these SUPN earnings landedvs 30 measured SUPN earnings reactions
| Middle 50% of SUPN earnings reactions | -2.75% to +3.12% |
|---|---|
| Median reaction (to close) | +1.07% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 SUPN earnings events with a measured close landed between -2.75% and +3.12%; 60% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +1.30% | -8.00% | |
| Supernus Announces Second Quarter 2026 Financial Results | Press release | +1.30% | -8.00% | |
| Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 | Press release | +0.13% | +1.68% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -0.40% | +1.54% | |
| Supernus Announces First Quarter 2026 Financial Results | Press release | -0.40% | +1.54% | |
| Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 | Press release | +1.34% | -0.71% | |
| Form 10-K SUPERNUS PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -0.09% | +0.53% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +1.03% | -1.60% | |
| Supernus Announces Third Quarter 2025 Financial Results | Press release | +9.80% | +5.39% | |
| Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 | Press release | +0.19% | -0.10% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +2.11% | +8.40% | |
| Supernus Announces Second Quarter 2025 Financial Results | Press release | +2.11% | +8.40% | |
| Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 | Press release | +0.06% | +0.36% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +6.00% | +2.25% | |
| Supernus Announces First Quarter 2025 Financial Results | Press release | +6.00% | +2.25% | |
| Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 | Press release | +0.00% | +1.65% | |
| Form 10-K SUPERNUS PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -2.53% | -5.00% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -2.26% | -8.60% | |
| Supernus Announces Third Quarter 2024 Financial Results | Press release | -2.26% | -8.60% | |
| Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results | Press release | +0.00% | +0.60% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +6.20% | +3.40% | |
| Supernus Announces Second Quarter 2024 Financial Results | Press release | +6.20% | +3.40% | |
| Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 | Press release | +0.00% | +2.29% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +3.14% | -4.82% | |
| Supernus Announces First Quarter 2024 Financial Results | Press release | +3.14% | -4.82% | |
| Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 | Press release | -0.60% | -2.40% | |
| Form 10-K SUPERNUS PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +4.27% | +8.75% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | -1.64% | +4.56% | |
| Supernus Announces Third Quarter 2023 Financial Results | Press release | -1.64% | +4.56% | |
| Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023 | Press release | +0.00% | -2.86% |
Keep exploring
More SUPN: analyst actions → · SEC filings → · SUPN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Celyad Oncology SA - American Depositary Shares (CYAD) | 504 | 0.00% | 41% |
| DELMAR PHARMACEUTICALS (DMPI) | 504 | -0.13% | 38% |
| CORINDUS VASCULAR ROBOTICS INC (CVRS) | 503 | -0.65% | 37% |
| Teligent, Inc. (TLGT) | 502 | -0.17% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.